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TARGETS OF HSA-MIR-488* IN HUMAN PROSTATE CARCINOMA CELLS
JINANI ELIAS SLAIBI
ABSTRACT

Prostate cancer (PCa) is one of the most prevalent forms of cancer among
men in America and is second only to lung cancer as a cause of cancer-related
deaths in men. Recent epidemiological study shows that one in every six men
over the age of forty five is at risk of PCa. Androgen receptor (AR) plays a
causative role in the development of PCa. Hormonal blockade therapy which
inhibits the expression of AR eventually fails and disease progresses to fatal
androgen-refractory stage from androgen-dependent stage. Therefore, novel
molecular approaches which can target and block the expression of AR are
required. We propose that microRNAs (miRNA) that function as negative gene
regulators have potential as PCa therapeutics. Using bioinformatics methods, we
have identified that human miRNA hsa-miR-488* has potential to modulate AR
expression. In the present study, we have validated the target site in AR 3’UTR
and established that AR is a target of Hsa-miR-488*. Our data show that the
ectopically expressed hsa-miR-488* as well as the synthetic miRNA mimic can
suppress the expression of luciferase activity in chimeric plasmid harboring
AR3’UTR with dose dependent effects. In addition, miR-488* negatively
regulated the expression of endogenous androgen receptor in PCa cells LNCaP.

V

Thus hsa-miR-488* that function as negative gene regulators has potential as
PCa therapeutics.
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CHAPTER I
INTRODUCTION

1.1 Cancer:

Human body is made up of about 100 trillion of living cells (Campbell, N.A. et
al. 2006). Normal cells carry a complete organismic genome which is far more
information that any cell may require (Sinden, R.R. 1994). Regulation of the cell
cycle is critical for the development of multicellular organisms. Part of this
information in normal cells controls essential function for the normal survivor of
cells such as growth, dividing, and dying in an orderly way. However, cancer
cells have lost the ability to control growth and division leading to uncontrolled
proliferation and the inappropriate survival of damaged cells. This new fate of the
uncontrolled cells is responsible for the formation of tumors.
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Cells have developed several safeguards to ensure that cell division,
differentiation and death occur correctly and in a coordinated fashion, both during
development and in the adult body (Esquela-Kerscher A. et al., 2006). Mutations
into this genomic information divert cells into acquiring novel of abnormal
phenotypes and incompatible features with normal cell cycle. These mutations
may cause inability of cells to make a functional signal, or cause it to code for a
protein that sends an incorrect signal to the cell (Kinzler K.W. et al. 2002). Most
mutations are repaired by the cell, but in rare cases mutations do not get
repaired. If a mutation is not repaired before a cell copies its DNA and divides
into two cells, then the mutation is passed on to the two new daughter cells and
becomes permanent. Some genetic disorders may cause cells deprivation of
their ability to repair DNA, and may therefore experience buildup of mutations.
Not all the mutations within the cell's DNA have effect on whether the cell will
become cancerous or not (Sawyer S.A. et al. 2007). However, protein signals
coded by a very small proportion of the total genes in each cell regulate cell
growth and division. These regulatory genes include the two groups of genes
called Proto-oncogenes and tumor-suppressor (Chial, H. 2008). A series of
mutations in the DNA of either and/or both groups of these growth controlling
genes is selected in cancerous cells. Thus cancer is considered to be a genetic
disease

and

the

cancer-forming

process

is

called

Tumorigenesis

or

Oncogenesis, where most cancers may arise through a combination of avoidable
or unavoidable carcinogens (Lutz W.K. et al, 1988).
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Many factors contribute to the transformation of normal cells into malignant
cancerous cells such as exposure to carcinogens, genetic defects, life style or
even viruses (Couch D.B. 1996). Cancer cells have gained the ability to grow and
multiply out of control forming a large mass of tissue called a tumor. Some
tumors are limited to one location and can be surgically removed. These tumors
do not grow in an unlimited, aggressive manner, do not invade surrounding
tissues and do not metastasize. This type of tumors is termed benign tumor
(Ramzi C.et al. 1999). But in other cases of cancer, cells have gained the ability
to spread and metastasize to surrounding tissue or other organs of the body.
Such aggressive tumors are termed malignant. The term cancer is used to
describe malignant, non benign tumors.

1.2 Prostate cancer remains a significant public health problem in the U.S.

Prostate cancer is the most common solid tumor form of cancer among men
in America and is second only to lung cancer as a cause of cancer-related
mortality (Jemal A. et al. 2008, 2005 ; Parker S.L et al. 1997). Despite earlier
diagnosis and improvement in treatment modalities, the cancer’s projection for
2009 estimated that 192,280 new cases of prostate cancer will occur in the US
during 2009 and 27,360 men will die from the disease (ACS, 2009).

3

Figure 1: Statistical figures were adopted from the 2009 American cancer Society
statistical study and rearranged in order to show the comparison between occurrence of
cancer cases and the mortality rate of each site. Prostate cancer is the most diagnosed
cancer within men and the second cause of cancer death in American men.

Numerous studies have shown that approximately 85% of newly diagnosed
prostate cancer cases are localized in the prostate, and the remaining 15 % of
the cases represents invasive or metastatic disease (Cooperberg MR et al.
2004). Those studies have provided insight into molecular mechanisms that
contribute to the beginning and progression of prostate cancer. Most of these
studies have suggested that androgens play an important role in the
development, regulation and progression of prostate cancer. Hence, the first line
for treatment is the Androgen deprivation therapy either surgical or chemical
castration through a complete hormonal blockage of androgen by using anti-
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androgens and in most cases combined with radiation in specific settings
(Harries W. et al, 2009; Taneja S.S, 2003). While most patients with prostate
cancer initially respond to androgen-ablation therapy, however 20% are
refractory to such treatments. Furthermore, majority of the patients who respond
to androgen ablation therapy eventually relapse with androgen-independent
prostate cancer (AIPC) within three years (Calabro F. et al, 2007).

1.3 Two stages of Prostate cancer:

The ligand-activated transcription factor, androgen receptor (AR), plays a
central role in the development and progression of prostate cancer in humans.
AR is heterogeneously expressed in primary tumors and throughout the
progression of androgen dependent and androgen independent ‘hormonerefractory prostate cancers. Prostate cancer initiates as an androgen-dependent
disease, and further accumulation of multiple sequential genetic and epigenetic
alterations transforms it into an aggressive, therapy resistant, androgenindependent prostate cancer (AIPC) (Maitland J.N. et al, 2008).
The molecular basis of the transition from androgen dependent to AIPC is still
unclear however; recent studies suggest that hypersensitivity of AR to trace level
androgens combined with androgen ablation therapy could provide a selective
pressure on the cellular pathways which are regulated by androgen signaling
(Taplin, N.E et al, 1999; Craft N. et al, 1999). Consequently, androgen dependent
cancer cells adapt to the androgen-deprived conditions and furthermore select
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mutated AR that is able to utilize an anti-androgen antagonist as an agonist for
their aggressive growth and proliferation (Marques, R.B et al, 2005).
Despite all the evidences, it is far from clear as to how AIPC arises and the
definitive roles played by the AR.

1.4 Mechanism of action of Androgen receptor:

Prostate cancer is dependent on androgen stimulation mediated by the
androgen receptor (AR). AR, a steroid hormone receptor member of the large
nuclear receptor superfamily, is a ligand activated transcription factor that
regulates the growth and the development of the normal prostate and plays a key
role in the pathogenesis of prostate cancer (Balk S.P et al., 2002; Quigley C.A et
al.1995).
Androgens stimulate proliferation and inhibit apoptosis, thus maintain the
ratio of proliferating cells to those dying. The maintenance of this ratio is very
critical for the normal growth of prostate cells (Feldman B.J and Feldman D.,
2001). Testosterone and diyhdrotestosterone (DHT) are the major androgens in
men. Testes produce over 90% of the hormone testosterone and the remaining
small fraction 5-10 % is synthesized in the adrenal glands. The largest
concentration of testosterone is circulating in the body, while most of the DHT’s
concentration is present in the prostatic tissues (Labrie FMD, 2004). About 75 %
of DHT is produced by the prostate and the skin while the remaining 25 %
circulating DHT is produced by the testes (Imamoto T. et al. 2008).

6

Figure 2: Mechanism of action of Androgen receptor: Testosterone enters cell
membrane to the cytoplasm, were it is converted to DHT by 5 alpha-reductase enzyme
(5αR). In the presence of DHT, AR will dissociate from the HSP and bind to DHT,
leading to conformational changes in the AR. Upon the phosphorylation of AR
homodimer it enters the nucleus and binds to the genes containing the androgen
response element, resulting in biological responses. Bartel et al 2004.

After being secreted by the testes, the testosterone hormone circulates in the
blood flow. When it reaches the prostatic tissues, the testosterone enters the
prostate cell membrane to the cytoplasm. In the cytoplasm, almost 90% of the
testosterone is converted by 5 alpha-reductase enzyme (5αR) to DHT.
Diyhdrotestosterone has much stimulatory effect on prostate cells growth

7

compared to testosterone and it has 5 fold higher affinities for AR than
testosterone (Feldman and Feldman, 2001; Montgomery et al 2009).
Androgen receptor contains an N-terminal domain which is known as the
regulatory domain and contains also two other domains: the first is a DNA
binding domain (DBD) and the second is the ligand binding domain (LBD). In
addition, AR has a hinge region that connects the Ligand binding domain to the
DNA binding domain, followed by C-terminal domain (Brinkmann A.O., et al
1989).
In basal state, AR binds to the heat shock protein complex (HSP). This
binding has the role of a chaperone to maintain the AR in a ligand-binding
conformation (Balk S.P, 2002). In the presence of DHT, AR dissociates from the
HSP and bind to DHT. This interaction leads to conformational changes in the
AR and results in the formation of a homodimer which is phosphorylated by
protein Kinase A (Feldman & Feldman, 2001; Balk S.P, 2002; Lynne V. et al,
1996).
Upon the dimerization and phosphorylation of androgen receptor, the
newly formed complex enters the nucleus where it binds to the androgen
response element in the promoter regions of the target gene (Chen C.Z et al,
2004). This binding will lead to the recruitment of co-activators and co-repressors
which results in biological responses by triggering the translation process leading
to up or down regulation of specific gene transcription (Feldman & Feldman,
2001; Balk S.P, 2002).
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Up-regulation or activation of transcription results in increased synthesis of
mRNA which in turn is transcribed by ribosomes to produce specific proteins.
Thus a change in the levels of specific proteins in cells is one way by which
androgen receptors control cell behavior.

1.5 Regulatory noncoding microRNAs (miRNAs):

MicroRNAs are a large family of phylogenetically conserved short,
endogenous, single-stranded, 20-25 nucleotide long, noncoding RNAs molecules
that can regulate gene expression in many different organisms ranging from
viruses to plant to worm and humans (Lee R.C et al, 1993; Chen C.Z et al., 2004;
Pasquinelli A.E. et al, 2000) ( Appendix: Table I and Figure I) . The best known
founding members of this family are lin-4 and let-7 of Caenorhabditis elegans
(Lee R.C et al, 1993; Pasquinelli A.E. et al, 2000). To date, more than 10,884
miRNAs have been annotated and 721 of these are human miRNAs. (miRbase,
Release 14, Sep 2009). These numbers are likely to change when many more
tissue specific miRNAs would be discovered by small RNA cloning and
sequencing strategies. miRNAs regulate the expression of thousands of target
mRNAs; each target mRNA has been predicted to be regulated by multiple
miRNAs.
Computational analysis suggests that over 30% of human genes are
regulated by miRNAs. Genes that are potentially targeted by these miRNAs
include cell growth and maintenance, signal transduction, cell proliferation,
9

phosphorylation, cell cycle, transcription factors, cell organization and biogenesis
(Nilsen T., 2007). In animals, miRNA mediates gene expression through
translational repression of its target mRNA by binding at the 3’ untranslated
region (UTR) in imperfect complementarity (Wightman B. et al, 1991).
Many examples of documented miRNA functions were discovered in
animals and include regulation of signaling pathways, apoptosis, metabolism,
cardiogenesis and brain development (He L. and Hannon J., 2004).
miRNAs may play a critical role in the process of tumorigenesis since a
deregulation of these biological processes are frequently occurred in human
cancer (Wenyong Z., et al., 2007). Evidence suggests that miRNAs can
contribute to carcinogenesis by acting as tumor suppressors or oncogenes since
they usually suppress the expression of oncogenes or proliferation related genes
(Xu-Bao S., et al., 2008). For instance, miR-15a and miR-16-1 are deleted or
down-regulated in the majority of Chronic Lymphocytic Leukemia (CLL) and
negatively regulate the antiapoptotic B cell lymphoma 2 (Bcl2) protein resulting in
induced apoptosis in a leukemic cell line model. (Cimmino A., et al. 2005).
Although many miRNAs are found to be significantly differentially expressed in
different cancer types, to date, only a few have been well characterized for their
functional significance.
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1.6 Relative genomic location of miRNA:

Scientists identified three groups of miRNA genes based on genomic location
relative to protein coding gene locus:
1. Intronic miRNA in protein coding transcription units (61%) e.g: miR-10 in
HOX4B gene (Lagos-Quintana et al., 2003; Lim L.P et al., 2003).
2. Intronic miRNA in noncoding transcription units (18%) e.g: miR-15a-16-1
cluster found in the fourth intron of a previously defined noncoding RNA
gene, DLEU2. (Narry K. and Jin-Wu N., 2006)
3. Exonic miRNA in noncoding transcription units (20%), such as miR-155.
(Cai X. et al, 2004; Lee et al., 2004).
MicroRNA genes are found in regions of the genome as separate transcriptional
units as well as in clusters of polycistronic units coding for several miRNAs. It
was found that approximately half of known miRNA exist in non-protein coding
RNAs (intron and exon) or within the intron of protein coding genes (Erdmann,
V.A., et al. 2004).
MicroRNAs that reside in introns share the same promoters and regulatory
elements of their host gene (Sikand K. et al., 2009) as for the other miRNA genes
transcribed from their own promoters, few primary transcripts have been entirely
identified (Lagos-Quintana M., et al., 2001; Lau N.C. et al., 2001).
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Computational analysis suggested that 60% of protein encoding genes may be
regulated by miRNAs. This fact suggests some important, yet undiscovered
regulatory mechanisms linked to miRNAs. A significant number of miR genes
(52.5%) are in cancer-associated genomic regions or fragile sites (FGA) (Calin
G.A. et al., 2004).
1.7 microRNAs Processing:

Little is known about transcriptional processes for miRNAs. It has been
shown that miRNAs control gene expression by binding to the complementary
sites in the 3’ untranslated regions (3’UTRs) of target mRNAs and triggering
therefore either translational inhibition or mRNA degradation by a molecular
mechanism that is actively investigated (Wightman B. et al, 1991; Zamore D.,
2005; Hutvagner & Zamore, 2002).
The majority of microRNAs are transcribed by RNA polymerase II from
different genomic locations as long primary transcript of about 125 nucleotides in
length, with a stem-loop structure known as (pri-miRNA) (Figure 3) (Lee et al,
2002; Cai X. et a.l, 2004; Kim V.N et al., 2005). Initially it was thought that
miRNAs are transcribed by RNA polymerase III (PolIII) (Cai X. et al, 2003),
however some of the pri-miRNAs are several kilobases long hosting some
stretches of more than 4 uracile nucleotides, which is unfavored by Pol III and will
ultimately lead to the termination of transcription by Pol III (Lee Y. et al., 2004).
Recently it is believed that Pol II is responsible for transcribing the majority of
miRNAs (Cai X. et al, 2004; Kim V.N et al., 2005).
12

Subsequent to transcription in the nucleus, the pri-miRNAs are further
processed by Drosha, RNase-III endonuclease. This enzyme belongs to the
family of double stranded RNA specific ribonucleases (Cai X. et al, 2003).
Drosha functions as a large protein complex called Microprocessor complex. This
large nuclear protein complex (about 550 kDa) plays the role of pri-miRNAs
metabolizing machinery.

The Microprocessor is composed of the enzyme

Drosha bound to a dsRNA-binding protein known as DGCR8 as well as many
other splicing factors (Gregory R.I et al, 2004). Upon the processing of pri-miRNA
by the Microprocessor complex, a shorter stem-loop shaped RNAs called
precursor miRNA (Pre-miRNA) is formed, that is about 70 nt RNAs with 2-3
nucleotides 3’ overhangs, 25-30 base pair stem containing multiple bulges and
mismatches with relatively small loops (Lee Y. et al, 2003). Pre-miRNAs bearing
a base-paired 5’ end and 3’ overhang of about 3 nucleotides are then transported
to the cytoplasm by Exportin 5/RAN-GTP complex (Yi et al, 2003; Bohnsack et al
2004; Gwizdek et al, 2003).
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Figure 3: microRNA
processing model:
microRNA (miRNA) genes are
transcribed by RNA Polymerase
II (Pol II) to form large primiRNA transcripts, which are
capped and polyadenylated.
These pri-miRNA transcripts are
processed by the RNase III
enzyme Drosha and its cofactor, to release the ~70nucleotide pre-miRNA precursor
product.
RAN–GTP
and
exportin 5 transport the premiRNA into the cytoplasm.
Subsequently, another RNase
III enzyme, Dicer, processes the
pre-miRNA to generate a
transient
~22-nucleotide
miRNA:miRNA*
which
will
eventually result in mature
single stranded miRNA (Lee Y.
et al, 2003).
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In the cytoplasm, pre-miRNAs are cleaved by Dicer, cytoplasmic RNase
III-type enzyme. Dicer contains two RNase III domains, each domain cuts
independently one RNA strand of the pre-miRNA complex yielding a product of
about

22 nucleotides in length with 2-3 nucleotides overhang, during this

process the duplex is unwound by unknown helicase-like enzyme (Kolb F.A. et
al, 2005). Subsequently one strand dicer cleaved pre-miRNAs called the mature
miRNA is incorporated into effecter complexes that are known as ‘miRISC’
(miRNA-containing RNA-induced silencing complex) (Hutvagner and Zamore ,
2002). miRISC complex delivers mature miRNA to its target mRNA through base
pairing with the 3’ untranslated regions (UTR) (Bartel D.P et al., 2004).
miRNAs control gene expression by binding to the complementary sites in
the 3′ untranslated regions (3′ UTRs) of target mRNAs (Figure 4), however, the
target sequence inserted into the 5’UTR or the coding sequences are also
functional (Kloosterman W. et al, 2004). If the miRNA has perfect or near-perfect
complementarity to the 3’UTR of target mRNA, it will result in mRNA
degradations (Figure 4 A) (Hutvagner & Zamore 2002; Bartel D.P et al., 2004).
On the other hand, the presence of multiple mismatches between miRNA
sequence and mRNA of target site, leads to translational inhibition without
affecting mRNA levels of target site (Figure 4 B) (Bartel D.P et al., 2004).
Molecular mechanism underlying either miRNAs mRNA mediated degradation or
miRNAs mediated translation repression are not fully understood, thus both
mechanisms are subject of intense investigation.
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Figure 4: miRNAs control gene expression: MiRNAs that bind to their mRNA targets
with perfect complementarity induce target-mRNA cleavage Panel A. The mature miRNA
binds to complementary sites in the mRNA target to regulate gene expression in one of
two ways, miRNAs that bind to mRNA targets with imperfect complementarity block
target gene expression at the level of protein translation Panel B.

1.8 Hsa-mir-488* and Hypothesis:

Recent studies reported that some miRNAs might play an important role in
prostate cancer by targeting the expression of some growth regulatory genes.
These miRNAs include miR-15 (Bonci D. et al, 2008), miR-101 (Varambally S. et
al, 2008), miR-125b (Lee C.Y. et al, 2005), miR-221 (Folini M. et al., 2009).
Unexpectedly, no miRNA yet to date has been reported to regulate androgen
receptor in prostate cancer, despite the fact that androgen receptor ablation has
been found to inhibit cell proliferation, thus demonstrating the essential functional
role of AR in the growth of prostate cancer cells. We hypothesized that miRNAs
may be involved in the regulation of androgen receptor signaling and these
miRNA could be used for targeting androgen receptor in prostate cancer. Using
16

computational analyses, we identified a potential target site for hsa-miR-488* in
the 3’ untranslated region of androgen receptor mRNA.
Hsa-miR-488* encoded in intron 5 of Astrotactin 1 (ASTN1) gene (Figure 5).
Astrotactin is a neuronal adhesion molecule required for glial-guided migration of
young postmitotic neuroblasts in cortical regions of developing brain, including
cerebrum, hippocampus, cerebellum, and olfactory bulb (Flink et al, 1995).

Figure 5: Astrotactin gene host the intronic region that code for Hsa-mir-488*. Hsa-mir488* encoded in intron 5 of the ASTN 1 gene.

This work investigated the methods to validate miR-488* target site in the
proposed gene (AR). What are some of the effect of miR-488* on its targets in
prostate cancer cells, and could this technique be used on different target sites?
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CHAPTER II
MATERIALS AND METHODS

2.1 Cell Lines and Cell Culture:
LNCaP:
The androgen-dependent human prostate carcinoma cell line LNCaP, was
obtained from American Type Culture Collection ATCC (Manassas, VA). LNCaP
cells were cultured in appropriate cell culture grade plates with 1X RPMI 1640
medium supplemented with 10% Fetal bovine serum (FBS) Atlanta Biologicals,
Inc. (Lawrenceville, GA) 2mM L-glutamine and antibiotics (100 units/ml of
penicillin G sodium, 100µg/ml streptomycin sulphate). LNCaP cell lines were
maintained in a humidified 5% CO2 at 37°C.
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CHO:
Chinese Hamster Ovary cell line CHO, was obtained from American Type
Culture Collection (Manassas, VA). CHO cells were cultured either in 6 well or 24
well plates with 2 ml or 500µl of Dulbecco’s Modified Eagle’s Medium (DMEM)
respectively, supplemented with 2 mM L-glutamine, 4.5 g/l Glucose, 5% Fetal
bovine serum (FBS) Atlanta Biologicals, Inc. (Lawrenceville, GA), 1 mM Lproline, 10mM HEPES and antibiotics (100 units/ml of penicillin G sodium;
100µg/ml streptomycin sulphate). Trypsin 1X was added up to 2 ml of cells and
incubated at room temperature for 3 minutes. Trypsin 1X was quenched with 3
ml of DMEM 1X supplemented with 5% FBS, 1mM L-proline, 10 mM HEPES and
antibiotics. Cells were finally seeded at an approximate density of 3.0 x 104
cells/well for 24 well plates and 1.0 x 105 cells/well for 6 well plates. All cell lines
were maintained in a humidified 5% CO2 at 37°C.
2.2 miRNA target validation:

miRNA is an emerging field of since and the knowledge about miRNAs
target still limited. Researcher in the field of miRNA combined computer
algorithms with biological information after the establishment of the human
genome to identify and predict target site for miRNAs. This new field of science is
called bioinformatic in our lab we have used bioinformatic methods, to identify
miRNAs which can potentially bind to the 3’ UTR of the AR. Several miRNAs
target prediction tools such as TargeSCAn, MirSCAN, Find TAR and RNAhybrid
have identified that hsa-mir-488* could potentially base-pair with the 3’ UTR of
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the androgen receptor. Hsa-mir-488* has extended base-pair matching sequence
to the seed region of the predicted site 10 nucleotide and minimal none
Watsoncrick

base

paring

(1

G:

U).

Overall

hsa-mir-488*

has

80%

complementarities to the predicted target site suggesting that AR 3’UTR could be
targeted by hsa-mir-488* (Figure 6).

RNAhybrid – Results (QueryID: bibiserv_1269872147_3730)

Figure 6: base pair alignment of AR3’UTR wild type and miR-488*: seed region
consist of 10 base pair with perfect complementarity, straight line (I) represent
Watsoncrick base paring, and (:) represent G:U non watsoncrick interaction.

2.3 Cloning of 3’ UTR AR in pMIR reporter Vector:
Full length wild type AR 3’UTR:
Primer name
AR

3’

forward
AR
reverse

Primer sequence

UTR 5′-GCGCACTAGTACGTTTACTTATCTTATGCCACGGG-3′
SpeI site
3’UTR 5′-GCGCAAGCTTGTTTGCTTGTTTTTGTTTTGATTTC-3′
HindIII site
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For the construction of AR 3′ UTR reporter plasmid, two primers (table 1) AR 3’
UTR forward and AR 3’UTR reverse were designed to

introduce SpeI and

HindIII sites (underlined) at the end of PCR product of 637 bases fragment of AR
3′UTR spanning the predicted target site for hsa-miR 488* ( Appendix, Fig 2) .
Thermodynamic analysis of the primers was conducted using computer
program: Primer Express (Applied Biosystems, Foster City, CA). The resulting
primer sets were compared against the entire human genome using NCBI to
confirm specificity and ensure that the primers flanked hsa-mir-488* target site on
the androgen receptor 3’UTR.
AR 3’UTR with both restriction sites was amplified through PCR
technique using the following PCR conditions.
PCR conditions:

Reagent
5X Buffer
Mgcl2
dNTP
PCR water
AR 3’UTR forward Primer
AR 3’UTR reverse Primer
Taq polymerase enzyme
human gDNA

Volume
10µl
5µl
1µl
30.5µl
0.5µl
0.5µl
0.5µl
2 µl

Optimized Thermocycler Parameters:

1.
2.
3.
4.
5.
6.

95 oC
95 oC
55 oC
72 oC
72 oC
4 oC

2 minutes
1minute
1minute
30 sec (go to 2 x 30 times)
10minutes
4hours
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Stock
5x
25 mM
10 mM
10 µM
10 µM
5 units/µl
50ng/µl

The resulted PCR product purified and concentrated using ZYMO research DNA
clean & concentratorTM-25 kit (ZYMO, Orange, CA) following the manufactory
protocol. After restriction digestion with SpeI and HindIII enzyme, the amplified
DNA was cloned into the corresponding sites of pMIR-REPORT vector (Ambion,
Austin, TX) downstream of firefly luciferase gene. The resulting plasmid construct
WT-3′UTR contains a strong CMV promoter driving a luciferase expression
cassette (Appendix, Fig 3).
2.4 Full length Mutated AR 3’UTR:

Site-directed mutagenesis of the putative target site for hsa-miR-488* in
WT-3′UTR construct was carried out in order to generate the MUT-3′UTR
constructs using the Change-IT Multiple Mutation Site Directed Mutagenesis kit
(USB Corporation, Cleveland, OH). In the first MUT-3′UTR construct, 10
nucleotides in the seed matching region of the target site were mutated to their
complementary nucleotides using primer
5’Phosphate

group

CTTATGCCACGGGAAGAACTCTCACGGAAGATTATCTGGGGAAAT
The newly generated construct was named AR 3’UTR seed MUT (Figure 7)
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Figure 7: base pair alignment of AR3’UTR seed MUT and miR-488*: mutations
introduce to the first 10 nt of the predicted target site (X) represent no interaction (I)
represent Watsoncrick base paring, and (:) represent G:U non watsoncrick interaction.

The second primer was designed to mutate the 5’ half of the putative miR-488*
site of the AR 3’UTR (Figure 8).
5’Phosphate

group

CTTATGCCACGGGAAGAACTCTCACGGAAGTAATAGACCCGAAAT

Figure 8: base pair alignment of AR3’UTR 5’ MUT and miR-488*: mutations
introduce to the 5’ half of the predicted target site (X) represent no interaction (I)
represent Watsoncrick base paring.

Both of the mutated constructs AR3’UTR seed MUT and AR3’UTR 5’MUT, as
well as a new construct combining both mutations on the same backbone were
generated following Change-IT Multiple Mutation Site Directed Mutagenesis kit
manufacturer protocol. Nucleotide sequences of the constructs were confirmed
by DNA sequencing.

23

2.5 Construction of vector expressed miR 488* “Pre-miR-488*”:

Segment of 383bp from intron 5 of ASTN 1 gene harboring the precursore
sequence of miR 488* along with a flanking region was amplified from human
genomic DNA using the following primers carrying XhoI and BamHI sites (Table
3).

Primer name

Primer sequence

Pre-488*

5′- GCACCTCGAGTGGGAGTGAGGGAGGCGGGGGAAG-3′

forward
Pre-488*
reverse

XhoI
5′- GCACGGATCCCCCCCAATCCTTGCCTAGCTCAAAC-3′
BamHI

The XhoI-BamHI digested amplified DNA was cloned into the corresponding sites
in pcDNA 3.1 (-) vector (Invitrogen, Carlsbad, CA). This construct was named
Pre-miR 488*. The primer validation and cloning method were performed as for
previous construct (Appendix, Fig 6).
2.6 Transient Transfection:

Equal cell numbers (3.0 x 104 cells/well for 24 well plate and 1.0 x 105
cells/well for 6 well plates) were seeded twenty four hours prior to transfection in
DMEM 1x Supplemented with 2mM L-glutamine, 4.5 g/l Glucose, 5% Fetal
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bovine serum (FBS) Atlanta Biologicals, Inc. (Lawrenceville, GA ), 1mM Lproline, 10mM HEPES, but no antibiotics. Two Transfection procedures have
been used:
Transfection via lipofictamein 2000:
This method was used with all transfections with miRNA mimic in 24 well
plates. Two separate solutions were prepared as following:
-

Solution I: In an Eppendorf tube, 0.75 µl of lipofectamin 2000/well was
added to 50 µl of free serum free P/S CHO media. After gentle mixing
through pipetting, the solution was incubated at room temperature for 5
min.

-

Solution II: In an Eppendorf tube, 100 ng of AR 3’UTR firefly luciferase
reporter construct was added to 50µl of free serum free P/S CHO
media and then mixed with 0.5 ng of Renilla luciferase reporter
plasmid. Finally, 10 nM of miR-488* mimic was added to the mixture. A
Negative Control for the microRNA (NC mimic) was also prepared by
adding 10nM of NC mimic to the mixture instead of miR-488* mimic.

Solution I and Solution II were mixed gently three to four times by pipetting and
then incubated at Room temperature for 20 minutes.
The total volume of 100 µl of Transfection mixture (Solution I + Solution II) was
added drop by drop to the corresponding labeled wells which already contain
500µl of DMEM 1X supplemented with 2 mM L-glutamine, 4.5 g/l Glucose, 5%
Fetal bovine serum (FBS) Atlanta Biologicals, Inc. (Lawrenceville, GA ), 1mM L25

proline, 10mM HEPES, but no antibiotics . The 24 well transfected plate was
incubated in a humidified 5% CO2 incubator at 37°C for 48 hours.
Transfection via polyBrene:
This method was used to transfect CHO cells with Pre-miR-488* construct
in 24 well plates. In an Eppendorf tube, 1.5 µl of PolyBrene10µg/µl was added to
500µl of free P/S CHO media. After mixing the required amount of PolyBrene
and free P/s media, the required concentrations of Pre-miR-488* was added. 100
ng of AR 3’UTR firefly luciferase reporter construct was added to the previous
solution and then mixed with 0.5ng of Renilla luciferase reporter plasmid. Finally
the mixture was incubated at room temperature for 5 min. Meanwhile the CHO
medium was aspirated from the wells and the previously prepared transfection
mixture was added to the designated wells. For the followed eight hours, the
transfected plates were maintained in a humidified 5% CO2 atmosphere at 37°C
incubator with gentle swirling every one hour. Eight hours later, the Transfection
media was aspirated out of the wells and the DMSO (Dimethyl Sulfoxide) shock
was performed by adding 500 µl of 30% DMSO/ CHO media. The cells were
incubated in the Shock medium at room temperature for 5 minutes. A washing
step using 500 µl of CHO complete media was done, and then another 500µl of
freshly prepared CHO media was added to each well. Finally, the transfected
plates were maintained in a humidified 5% CO2 atmosphere at 37°C incubator for
fourty eight hours from DMSO shock point.
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2.7 RNA Extraction:

Total RNA from experimental and control wells were isolated from 80%
confluent cells directly in the 6 well culture plate. Cells were homogenized in the
culture dish and lysed directly by adding 1 ml of TRIZOL® Reagent (Invitrogen,
Carlsbad, CA) following manufactor’s protocol. The cell lyzate was collected in
1.5 ml Eppendorf tube. Samples were treated with chloroform, incubated at room
temperature for 2 to 3 minutes and centrifuged (12,000 x rpm) for 15 minutes at 4
°C. The upper aqueous phase (approximately 450µl) was transferred to a fresh
tube and precipitated by adding 1 volume of isopropanol to extract RNA. After 10
minutes of incubation at room temperature, RNA pellet was collected by
centrifugation (12,000 rpm) for 10 minutes at 4° C. After discarding the
supernatant, RNA pellets were washed with 1 ml 75% ethanol/ DEPC water and
precipitated by centrifugation (12,000 rpm) for 5 minutes at 4°C. Pellets were
resuspended in 50 µl of Rnase-free water. RNA yield and purity were determined
spectrophotometrically at 260-280nm and the reliability of RNA was verified by
electrophoresis through 1 % denaturing agarose gels stained with ethidium
bromide.
2.8 Protein Extraction:

Additional wells containing experimental and control CHO cells were
seeded for protein extraction. Cells were washed once with 500 µl cold PBS in 24
well plates. 100 µl of 1X passive lysis Buffer (PLB) was added and the culture
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dish was gently rocked for 45 minutes at RT, then homogenized materials were
collected in microcentrifuge tubes. Slow centrifugation at 4000 rpm for 15
minutes at 4° C was performed to pellet down any unlysed cells. The Protein
quantification was determined by spectrophotometry at 595 nm and using 1X
Bradford reagent (Bio-Rad Hercules, CA). The total protein concentration was
calculated. Total protein lysates were stored at -80° C for further experimentation
procedures.
2.9 Dual Luciferase assay:

For Dual luciferase assays, CHO cells (30,000 cells/ well) were plated in
24-well plates one day prior to transfection. Cells were co-transfected using
lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA), with 100 ng of WT-3′UTR
or MUT-3′UTR firefly luciferase reporter construct, 0.5 ng of renilla luciferase
reporter plasmid and either miR 488* mimic (10 nM) or NC mimic (10 nM). Cells
were harvested and total protein concentrations were determined by Bradford
method 48 hours after transfection. 10 µg of total cell protein lysates were
assayed for firefly and Renilla luciferase activities using the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI) and Victor 3 Multilabel Counter
1420 (PerkinElmer). Aliquots of 10 µg of total cell protein lysates were transferred
into oblique 96 well plates and 100 µl of LAR II reagent (Promega, Madison, WI)
was dispensed into each well followed by orbital shaking for 2 seconds and
incubation time of another 2 seconds, then 10 seconds of measurement of the
emission light produced from the fire fly luciferase. Reading was recorded
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electronically. In order to quinch the emitted light from the firefly luciferase and to
activate the emission of light from Renilla luciferase, 100 µl of Stop & Glo®
reagent (Promega, Madison, WI) was added to the previous wells, followed as
before by 2 second of orbital shaking and 2 second of incubation time, then 10
second of measurement of emission of light produced by Renilla luciferase.
Readings were recorded electronically. The whole procedure was carried out at
room temperature.
2.10

Quantitative Real-Time (qRT) PCR Analysis of Mature miRNA

Expression:

From 10 ng of total RNA the first strand cDNA was synthesized using
primers specific for miR-488* and snoRNA 202. Both primers were obtained from
TaqMan MicroRNA Assays (Applied Biosystems Foster City, CA). Reagents for
cDNA synthesis were obtained from TaqMan MicroRNA Reverse Transcription
kit (Applied Biosystems). For each sample, a 15µl reverse transcription (RT)
reaction was set up containing 10ng of total RNA, 1X RT buffer, 1mM of dNTP
mix, 50 units of MultiScribe reverse trancriptase, 3.8 units of RNase inhibitor and
3µl of miRNA-specific RT primer. The reactions were incubated in a thermal
cycler (BIORAD PTC-100) at 16°C for 30 minutes, 42° C for 30 minutes, 85° C
for 5 minutes and then held at 4°C. The ‘reverse transcriptase minus’ controls
were also synthesized under the same conditions. In order to quantify the mature
miRNAs and snoRNA 202 in each sample, the cDNAs were amplified using
TaqMan MicroRNA Assays together with the TaqMan 2X Universal PCR Master
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Mix (Applied Biosystems Foster City, CA). For this step, a 20µl reaction was set
up containing 1.33 µl product from RT reaction, 1µl of 20X TaqMan microRNA
assay mix (mixture of miRNA-specific forward and reverse primers, and miRNAspecific TaqMan MGB probe labeled with FAM fluorescent dye) and 10 µl of
TaqMan 2X Universal PCR Master Mix. These reactions were dispensed into a
96 well optical plate (Applied Biosystems Foster City, Ca). The plate was
centrifuged at 2000 rpm for 5 minutes to remove any air bubbles that might be
formed. After insuring the absence of air bubbles, the plate was positioned in
7500 Real-time PCR System (Applied Biosystems) under the following
conditions: 95°C for 10 minutes followed by 50 cycles of 95°C for 15 seconds
and 60°C for 1 minute. Three replicates were performed per RT reaction together
with the ‘reverse transcriptase minus’ and ‘no template’ controls. Duplicate PCRs
were performed for all miRNAs in each RNA sample. The mean Ct was
determined from the replicates. The snoRNA 202 expression was used as an
invariant control. The relative expression of each miRNA was calculated as 2-ΔCt
where ΔCt = Ct value of each miRNA in a sample – Ct value of snoRNA 202 in
that sample. All experiments were repeated at least twice with three replicates
and two independent RNA samples (Appendix, Fig 7).
2.11

Statistical analysis:

To interpret our results, significance tests and statistical analysis are critical.
The traditional α-value, i.e., p = 0.05, was used to evaluate the statistical
significance of this study. The data of the dual luciferase and q-RT-PCR assays
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results will be expressed as the mean ± SEM and compared using student's ttest for normally distributed samples.

The results were analyzed using the

MYSTAT 12 version 12.02.00 statistical program (Systat Software, Inc.Chicago,
IL) and Microsoft Excel (Microsoft, Seattle, WA). The index of expression of each
miRNA was 2-ΔCt after normalization to snoRNA 202 expression levels. Hence,
results were considered statistically significant if p values were < 0.05.

31

CHAPTER III
RESULTS and DISCUSSION

3.1 Identifying potential target site for miR-488* in AR 3’UTR:

Androgen receptor (AR) plays a central role in the development and
progression of prostate cancer in humans. AR is heterogeneously expressed in
primary tumors and throughout the progression of androgen dependent and
androgen independent “hormone-refractory prostate cancers”. Prostate cancer
initiates as an androgen-dependent disease, and further accumulation of multiple
sequential genetic and epigenetic alterations transform it into an aggressive,
therapy resistant, androgen-independent prostate cancer (AIPC).
The molecular basis of the transition from androgen dependent to AIPC is still
unclear however; recent studies suggest that hypersensitivity of AR to trace level
androgens combined with androgen ablation therapy could provide a selective
pressure on the cellular pathways which are regulated by androgen signaling
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(Taplin, N.E et al, 1999; Craft N. et al, 1999). Consequently, androgen dependent
cancer cells adapt to the androgen-deprived conditions and furthermore select
mutated AR that is able to utilize an anti-androgen antagonist as an agonist for
their aggressive growth and proliferation (Marques, R.B et al, 2005).

MicroRNAs molecules can regulate gene expression in many different
organisms by functioning as negative gene regulators (lee et al, 1993; lee and
Ambrose, 2001; Bartel, 2004; Pasquinelli et al, 2000). In order to study the effect
of
had

miRNAs on AR, we
to

miRNA

identify
that

has

one
the

potential to bind to the 3’
untranslated

region

of

androgen

receptor.

Bioinformatic

programs

such

as

TargeSCAN,

Figure 9: Schematic representation of AR 3’UTR with
the location of miR-488* predicted target site: Hsa- MirSCAN, Find TAR and
miR-488* has extended seed region complementarity to
the predicted target site ( 10 bases ), followed by three
RNAhybrid
aided
in
bulges, resulting in 80% complementarity to the target
site, according to Bartel et. al this such interaction should
result in translation repression but not mRNA accomplishing this task

by predicting one target site in the AR 3’UTR.
Our bioinformatics results indicated that hsa-mir-488* has target site in the 3’
UTR of AR. Base pair interaction between the predicted target site and hsa-mir488* is shown in (Figure 9).

33

Furthermore, bioinformatics approaches showed that the predicted target site
is evolutionary conserved across different species (Figure 10). Those similarities

Figure 10: Cluster alignment of AR 3’UTR of different species: Sequence alignment
of the miR-488* putative predicted target site in the AR 3’UTR of five different species:
Target site boxed in green and stars indicate the conservation across all five species.

in sequence alignment serve as evidence for structural and functional
conservation, thus this predicted site might have an important function within the
development of these species.
In addition, precursor sequence for hsa-miR-488* encoded in intron 5 of
Astrotactin 1(ASTN1) gene in human is also highly conserved in five species
(Figure 11). This is a further evidence that miR-488* has an evolutionary
conserved role within the lineage of evolution. This extensive conservation
strongly indicates a more general role for hsa-miR-488* in developmental
regulation, as well as the predicted target site to be an authentic target site.
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Figure 11: Cluster alignment of precursor sequence of miR-488* in five different
species: Sequence alignment of pre-miR-488* in five different species, miR-488* mature
sequence in red box. Stars indicate the conserved nucleotides.

3.2 Effect of miR-488* on AR expression:

In order to experimentally test the potential of miR-488* to regulate the
expression of AR, my lab
colleague

Dr.

transfected

Sikand
PCa

Hormone dependent cell
line (LNCaP) with miR488* mimic or negative
control

(NC),

negative

control being a miRNA
from C. elegance that
Figure 12: Effects of miR-488* mimic on AR protein
expression: LNCaP cells were transfected with either has no target site in
miR-488* or NC mimic with the appropriate controls, cells
were collected after 48 hours, total protein estimation was human genome. After 48
performed followed by western blot analysis. Results
indicate high reduction of AR protein levels when
hours of transfection,
transfected with miR-488* mimic compared to cells
transfected with either NC mimic or mock transfected.

cells were collected and

total protein amount was estimated, then a western blot was performed in order
to determine the AR protein expression. β-Actin was used as an internal control.
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Results are shown in (Figure 12): when cells were transfected with different
concentration of miR-488* mimic, a high reduction of AR protein levels was
observed comparing to the cells transfected with the same concentrations of
negative control miR mimic. In addition, negative control mimic had no effect on
the AR levels compared to no transfection or mock transfection, which clearly
indicates that the change in AR protein levels is due to the effect of miR-488* on
the expression levels of Androgen receptor protein. Transient transfection of miR
488* mimic resulted in robust suppression of AR protein expression in LNCaP
cells.
3.3 Target Validation: Construction of Luciferase Reporter Plasmids

expressing AR 3’UTR.
In order to validate the previously observed
data, we have to demonstrate that the repression
of AR protein is due to the interaction between the
predicted AR mRNA target site and miR-488*. To
address this question, we cloned the AR 3’UTR
containing the putative wild type miR-488* target
site into the 3' multiple-cloning-site (MCS) of
pMIR-REPORT

vector

(Ambion,

Austin,

TX)

downstream of firefly luciferase gene as described

Figure
13:
Restriction
digestion clone confirmation:
AR 3’UTR clone was confirmed in the “materials and method” section. The
by double digestion with SpeI
and
HindIII
enzyme
and resulting plasmid construct WT-3′UTR contains a
analyzed on 1 % agarose gel.

strong

CMV
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promoter

driving

a

luciferase

expression cassette (Appendix, Fig 3). The resulted clones first were confirmed
by double digestion with SpeI and HindIII enzyme and analyzed on 1 % agarose
1X TAE gel and compared to 1 Kb ladder (Figure 13). As expected, a fragment of
637 base pair product was observed in two clones (clone #2 and clone # 8)
indicating that AR 3’UTR was cloned successfully into the MCS of pMIRREPORT. For further confirmation, the resulted clones were sequenced in the
Cleveland clinic foundation genomic core facility, and once again the sequence
result proved that indeed the cloned fragment is the AR 3’UTR.

37

3.4 Target Validation: Effect of miR-488* mimic on the chimeric AR 3’UTR

WT luciferase reporter plasmid:
To address if miR-488* could target the AR 3’UTR, we have transfected
the resulted chimeric sensor plasmid along with Renilla luciferase plasmid
and the appropriate controls as described in the materials and method section
into 80 % overnight grown CHO cells in the absence of antibiotics using
lipofectamine 2000 as transfection reagent of choice. After 48 hours post
transfection, cells were
collected, washed once with
1X PBS and lysed in 1X PLB.
Total protein was estimated
using Bradford reagent and 10
µg of total protein was loaded
into the designated wells of
the 96 well plates. Protein
lysates were assayed for
firefly and Renilla luciferase
Figure 14: Quantitative analysis of the chimeric
AR 3’UTR wild type luciferase plasmid repression
by miR-488* mimic: CHO cells were cotransfected
with chimeric AR 3’UTR luciferase reporter plasmid
along with Renilla luciferase plasmid and miR-488*
mimic (10nM) or NC mimic (10nM) are indicated.
Down regulation of 51% of the firefly luciferase when
transfectecd with miR-488* mimic was observed
compared to transfection with NC.
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activities using the DualLuciferase Reporter Assay
System (Promega, Madison,
WI) and Victor 3 Multilabel
Counter 1420 (PerkinElmer).

Results showed that the transfection of miR-488* along with chimeric
sensor plasmid (AR 3’UTR) resulted in down regulation of about 51% comparing
to transfection with negative control of the same concentrations. This result
indicates that miR-488* might be interacting and negatively down regulating the
AR 3’UTR chimeric plasmid. However we are certain that this result is due to the
interaction of miR-488* with the predicted target site and not with the body of
pmiR REPORT, since no down regulation was observed when pmiR REPORT
empty vector was transfected with the same concentration of miR-488* mimic
and NC mimic. Furthermore none of the microRNAs target prediction tools have
shown any target site for miR-488* in the empty pMIR report vector.
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3.5 Base pair interaction between miR-488* and predicted target site:

MicroRNAs mediate gene expression through translational repression of its
target mRNA by binding to the 3’ untranslated region (UTR) in imperfect
complementarity (Wightman B. et al, 1991; Bartel, 2004). MiR-488* has 80%
complementarity to the predicted site, thus it is believed to bind to the predicted
target site and through an ambiguous and not fully understood mechanism, drive
an expression repression of its target gene (Nilsen T, 2007). To validate if miR488*

is

directly

interacting with the
predicted target site,
a

new

harboring

construct
the

AR

3’UTR with mutated
seed region (first 10
nucleotides from 3’
Figure 15: Base pairing interaction between miR-488* and end of the predicted
predicted target site: Three constructs were generated, first
one harboring mutated seed region, second with mutated bulge target site) to its
region and third with mutated seed region as well as mutated
complementary
bulge region.

nucleotides was generated as described in “Materials and Method” chapter II.
Furthermore, a construct with the 5’ half of the predicted target site (bulge region)
was mutated to its complementary nucleotides. In addition, another construct
harboring both of the previously mentioned mutations within the same target
(Figure 15) was designed and generated. The first construct with seed mutations
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was named AR 3’UTR seed MUT; the second construct with bulge mutations
was named AR 3’UTR 5’ MUT and the final construct harboring seed mutations
as well as bulge mutations was named AR 3’UTR 3’/5’ MUT.
The three mutations were transiently co-transfected into CHO cells with miR488* mimic and NC mimic as well as renilla luciferase construct as a transfection
control with all the appropriate controls. Results are shown in (Figure 16). When
cells were transfected with the wild type AR3’UTR chimeric plasmid along with
miR-488* mimic, results were similar to previously obtained with repression of
luciferase expression of about 55% compared to transfection with NC mimic
(Figure 16A).
On the other hand, the co-transfection of the AR 3’UTR seed MUT chimeric
plasmid along with miR-488* mimic resulted in down regulation of about 33%
compared to NC mimic transfection (Figure 16B). A down regulation of about
58% of luciferase expression was observed when cells were co-transfected with
AR 3’UTR 5’MUT along with miR-488* compared to NC mimic (Figure 16C).
Unexpectedly, 45 % reduction of luciferase activity was observed when cells
were co-transfected with AR 3’ UTR 3’/5’ MUT with miR-488* mimic compared to
NC mimic (Figure 16D).
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Figure 16: Effect of AR 3’UTR mutations on the levels of luciferase expression in
the chimeric plasmid: CHO cells were co-transfected with either wild type AR 3’UTR
chimeric plasmid or mutated: Panel A, 55% reduction of luciferase expression was
observed when transfected with WT AR 3’UTR and miR-488* mimic. Panel B 33%
reduction of luciferase expression was observed when transfected with AR 3’UTR seed
MUT and miR-488* mimic. Panel C, 57% reduction of luciferase expression was
observed when transfected with AR 3’UTR5’ MUT and miR-488* mimic. Panel D, 45 %
reduction of luciferase expression was observed when transfected with WT AR 3’UTR
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Results from panel B and C compared to Panel A, suggest the seed region
seems to play a major role in the interaction between the miR-488* and the
predicted site in the AR 3’UTR. Nevertheless, results from Panel A and Panel D
suggest that there might be other putative sites within the AR 3’UTR mRNA
which can interact with miR mimic by Base-pairing. Presumably, these sites are
providing miR-488* mimic with substitutionally binding segments, when the first
original site (nucleotides 4266-4289) of the AR 3’UTR is mutated. Hence, the
down regulation of luciferase expression was still observed even with mutations
designed to interrupt interaction between miR-488* and the predicted target site.
3.6 Cloning Shorter AR 3’ UTR:

Next question we asked is: Are there any sites that miR-488* is binding to
other than the putative site (nucleotides 4266 – 4289)? To address this question,
careful observation of the Wild type AR 3’UTR sequence revealed the identity of
three sites which might serve as substitution binding sites (Appendix; Fig 4A).
Site one (nucleotides 158-168 from 5’ end of AR 3’UTR) is consisting of 10
nucleotides with 7 perfect matches to the seed region. Site two (nucleotides 293299 from 5’ end of AR 3’UTR) has 6 nucleotides with 4 perfect matches to the
seed region and site three (nucleotides 348-358 from 5’ end of AR 3’UTR) is 10
nucleotides with 8 perfect matches to the seed region (Appendix; Fig 4B).
Mutation Site Directed Mutagenesis kit (USB Corporation, Cleveland, OH) was
used as described in Chapter II, Section 2.4 to individually mutate each newly
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revealed sites. Resulted constructs with either mutations in Site I, II or III were
co-transfected individually with miR-488* mimic and the appropriate controls.
Data showed similar repression levels of fire fly luciferase ( 54 %, 53% and 52% )
for mutated site one, mutated site two and mutated site three, respectively as
compared to WT AR 3’UTR with 51% fire fly luciferase repression( Appendix; Fig
5).
These results did not explain neither proves if site one, two and three could
serve as substitution binding site for miR-488*. Since we did not have one
construct

harboring

all

mutated sites as well as
the mutated seed region
in the putative target site,
we decided to clone a

Figure 17: miR-488* mutated mimic alignment
with AR 3’UTR: miR-488* mutated mimic; this new shorter segment of AR
negative control have the same nucleotides as miR-488*
but with 4 nucleotides to be mutated to its complementary
bases in the seed region. Mutated nucleotides are 3’UTR (nucleotides 561indicated in blue color in seed region.

637 from 5’ end of AR

3’UTR (Appendix: Fig 4A & 4B). This segment (77 nucleotides) of AR 3

UTR

contained the wild type (Short AR WT) or seed mutated miR-488* target site
(Short AR seed MUT) in a luciferase reporter vector. For the following set of
experiments a new negative control (miR-488* mut mimic). This new control
harboring 4 mutated nucleotides to its complementary bases in the seed region
(Figure 17). miR-488* mut mimic was used along with the old negative control
from C. elegans.
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Each of these constructs was co-transfected with either miR-488* mimic or
negative control mimic in CHO cells and luciferase activity was measured after
48 hours.
miR-488* reduced luciferase activity of the Short AR WT construct by 30%
as compared to that with the NC mimic and miR-488* mut mimic. However, in
CHO cells transfected with Short AR seed mut chimeric luciferase reporter
plasmid, miR-488* was unable to suppress luciferase activity. Luciferase
expression in these cells was similar to that seen in cells co-transfected with
Short AR seed mut construct and either NC mimic or miR-488* mut mimic
(Figure 18).

Figure 18: Chimeric plasmid with Shorter AR 3’UTR can be targeted by miR488*: Mir-488* reduced luciferase activity of the Short AR WT construct by 30% as
compared to that with the NC mimic and miR-488* mut mimic. In CHO cells
transfected with Short AR seed mut, chimeric luciferase reporter plasmid, miR-488*
was unable to suppress luciferase activity. Luciferase expression in these cells was
similar to that seen in cells co-transfected with Short AR seed mut construct and
either NC mimic or miR-488*
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These data suggest that miR-488* putative target site within the shorter AR
3’UTR seems to be an authentic site. Also the reversal of luciferase expression
by miR-488* mut mimic suggests that only four nucleotides mutations in the seed
region are sufficient enough to disrupt the interaction between miR-488* mimic
and predicted target site which is consistent with the common line of thoughts for
microRNA mediated gene regulation (Nilsen T, 2007).

3.7 Dose dependent expression of mature miR-488* from Pre-miR-488*

expression plasmid:
To

study

the

effects of hsa-miR-488*
expressed
genomic

from

its

context,

an

expression
system

which

reporter
could

Figure 19:
Quantitative Real-Time (qRT) PCR experimentally enable us
analysis of mature miR-488* expression: An increased
dose dependent expression of mature miR-488* was to express the mature
observed respectively to increased concentration of
transfected pre-miR-488* chimeric expression vector.
form of miR-488* and

study its effects was required. To achieve this aim, a segment of intron five in
ASTN1 gene was PCR amplified from human genomic DNA and cloned between
XhoI and BamHI sites of pcDNA 3.1(-) under the expression of CMV promoter.
The cloned segment of intron 5 from ASTN 1 gene, codes for hsa-miR-488*
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precursor, along with both downstream and upstream flanking regions (Appendix;
Fig 6). This construct was named Pre-miR-488*. Overnight grown, 80 %
confluent Chinese Hamster Ovary cells were transfected with different
concentrations of Pre-miR-488* construct, using polybrene as transfection
reagent as described in materials and method. Cells were collected and total
RNA was extracted by mean of TRIZOL® Reagent. Quantitative real time PCR
technique was used to assess in detecting the mature miR-488* in total RNA
aliquots of 10 ng from each transfected concentration samples.
As expected no endogenous expression of miR-488* was detected in
untransfected

samples.

However,

samples

transfected

with

increased

concentration of pre-miR-488* (1.5, 2.0 and 2.5 µg) showed an increased
expression profiles respectively to amount of transfected plasmid expressing
genomic miR-488* gene (Figure 19). Cells transfected with 2.5 µg pre-miR-488*
expressed mature miR-488* by about 2 fold higher than those transfected with
1.5 µg. These results suggests a dose dependent expression of miR-488* gene
in transiently transfected mammalian cells.
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3.8 Dose dependent repression of Firefly luciferase expression by Pre-miR-

488* :
We have shown that synthetic miR-488* could down regulate the expression
of the chimeric luciferase reporter plasmid. Next we investigated whether miR488* gene can also repress the luciferase activity from the chimeric AR 3’UTR
plasmid.
To address this question, we transfected CHO cells with Short AR 3’UTR wild
type plasmid and short AR seed MUT plasmid along with increased
concentration of the pre-miR-488* expression plasmid. As for controls we
transfected a pool of the cells with empty expression plasmid (pcDNA 3.1 ) and
Renilla luciferase plasmid served as internal control for transfection. As shown in
Figure 19, Dual luciferase assay’s results of samples transfected with increased
concentrations of pre-miR-488* (1.5µg, 2.0µg and 2.5µg) have indicated a
reduction of luciferase activity of about (10 %, 20 % and 27 %) respectively, to
transfected concentration. However the sample of cells transfected with Short AR
seed MUT show reversal of luciferase expression similar to results obtained from
sample transfected with the empty expression vector. Results were normalized to
Renilla expression and represented in (Figure 20).
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Figure 20: Quantitative analysis of repression of luciferase sensor by Pre-miR-488*
expression vector: Luciferase and Renilla expression was measured with increased
concentration of transfected pre-miR-488* and with the highest concentration of pcDNA 3.1
empty vector along with the appropriate controls. All expression values and ratio of Firefly to
Renilla luciferase were plotted as a measurement of the translational repression of firefly
luciferase by ectopically expressed mature miR-488*.

These results were consistent with, observation from induction with
synthetic miR-488*. Thus, miR-488* gene expressed from its genomic context
have the same ability to target AR 3’UTR and repress the luciferase activity in the
chimeric plasmid. miR-488* gene expression profile (Section 3.7) show increased
levels of mature miR-488* expression respectively, to increased concentration of
transfected pre-miR-488*. Current data (Figure 20) once again enhance the
previous observation. The higher the concentration of transfected pre-miR-488*,
the higher is the concentration of the expressed mature miR-488*. These results
suggest a negative correlation between the amount of transfected pre-miR-488*
and the luciferase expression profiles.
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3.9 Mutations within miR-488* precursor in different cell lines:

Recent studies indicated that miR-488* predominantly expressed in adrenal
gland, adrenal cortex and mainly in brain tissues (Wang E, et al. 2009; Landgraf
P et al. 2007).However, we are not aware of any report linking miR-488* to
prostate cancer, thus we wanted to explorer wither miR-488* is expressed in
prostate cells.

Unpublished data by our lab have shown that miR-488* is

expressed at significantly low levels in androgen dependent cell line (LNCaP)
and similar results for the androgen independent cell line (C4-2B). However, no
signal for miR-488* was detected from androgen independent cell line DU145.
To further investigate these findings, both Forward and Reverse Pre-488*
primers shown in (Table 3; Chapter II) are great tools to perform PCR on
genomic DNA collected from several androgen dependent prostate cancer cell
line (LNCaP), androgen independent prostate cancer cell lines (DU145, PC3,
and CWR 22RV1), Brain tumor cell lines (U-87 and U251) and Human breast
adenocarcinoma cell line (MDA). Amplified segments were sequenced and
analyized by clustral alignement

in (Figure 21), along with the precursore

sequence for Hsa-miR-488*.

50

Figure 21: Cluster alignement of miR-488* stem-loop region in different cell lines: sequence
alignment of the stem loop region of miR-488* from androgen dependent prostate cancer cell line
(LNCaP), androgen independent prostate cancer cell lines (DU145, PC3, and CWR 22RV1), Brain
tumor cell lines (U-87 and U251) and Human breast adenocarcinoma cell line (MDA).

Interestingly, all cell lines show high conservation in stem loop region of hsamiR-488*,

with

only

one

point mutation in DU145
cells.

This

androgen

independent

cell

incorporated
substitution

a
in

C

line
to

G

nucleiotids

60. Interistingly, when both
wild type miR-488* stem
loop and the corresponded
stem loop from DU145 cells
(CG mutation at base 60)
folded

using

RNA-Fold

Figure 22: Folding state of miR-488* stem loop: this
figure illustrate both folding state of wild type miR-488* stem
loop and the corspondend stem loop from DU145 cells (CG program, it revealed different
mutation at base 60)

structure (Figure 22).
It has been proposed that RNA:RNA interactions or RNA:protein interaction
are involved in structure recognition and processing precursor miRNA to mature
51

sequence (Kim et al , 2007). These results along with the mature miR-488*
expression profile might suggest that the CG mutaion at base 60 in DU145
contrbute to reduced expression of mature miR-488* in DU145 cell line.
Nevertheless, further study is required for better understanding for the role of the
CG substitution in the preocessing of miR-488*.
3.10

Stable cell line (LNCaP and C4-2B) expressing miR-488*:

Androgens stimulate proliferation and inhibit apoptosis, thus maintain the ratio
of proliferating cells to those dying. The maintenance of this ratio is very critical
for the normal growth of prostate cells (Feldman and Feldman, 2001). In prostate
cancer cells this ratio favoring the proliferation. Additionally, AR is required for
the proliferation of prostate cells (Feldman & Feldman, 2001; Balk, 2002).
However, we have shown in this study that AR is a direct target of miR-488*.
Thus, by stably transfecting miR-488* into prostate cancer cells can we once
again balance the ratio between proliferation and apoptosis?
To address this question, plasmid DNA Pre-miR-488* was linearized with
restriction enzyme, Bgl II and stably transfected into either androgen dependent
cell line (LNCaP) or androgen independent cell line (C4-2B). Stably transfected
cells were maintained in RPMI 1640 medium supplemented with 10% Fetal
bovine serum (FBS), with antibiotics and 100 µg/ml G-148.
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Figure 23: Stable cell line (LNCaP and C4-2B) expressing miR-488*: Panel A, Untransfected
LNCaP cells, Panel B, stably transfected LNCaP cells with Pre-miR-488*. Panel C, untransfected
C4-2B cells. Panel D, stably transfected C4-2B cells with Pre-miR-488*.

This selection media allows for only cells expressing the resisting gene
which is incorporated in Pr-miR-488* plasmid to survive.

All cell lines were

maintained in a humidified 5% CO2 at 37°C. An interesting observation, that
LNCaP cells (androgen dependent) did not grow well and number of cells were
low. While C4-2B cells continued to grow and higher number of cells was
observed. These results may suggest that more cells are dying to these
proliferating in the stably transfect LNCaP cells. On the other hand, it seems that
more cells are proliferating to these dying in the C4-2B (androgen independent
cell line). We cannot draw a conclusion whether this phenotype is due to the
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effect of miR-488* on androgen receptor or not. Further more study is required to
enhance our understanding of these two phenotypes.
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CHAPTER IV
FUTURE DIRECTIONS AND CONCLUSION

4.1 Implication of the CG substitution in mature miR-488* processing:

It has been proposed that RNA:RNA interactions or RNA:protein
interaction are involved in structure recognition and processing precursor miRNA
to

mature

sequence

(Kim

et

al

,

2007).

MiRNA

processing

is

a

compartmentalized process; precursor miRNA at first is made in the nucleus,
then it is processed into the mature miRNA in the cytoplasm. In order to study
whether the observed CG mutant in DU145 cells is affecting the nuclear process
of miRNA precursor or the cytoplasmic process of miRNA maturation; an in vitro
system could be used where the precursor sequence for miR-488* is cloned
downstream of T7 promoter in one construct. Second construct harboring the
precursor sequence for miR-488* along with the observed CG mutation at the
indicated position (nucleotide 60) will be cloned downstream of T7 promoter.
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After radiolabeling both constructs, they could be used for in vitro miRNA
processing system with total cellular extract from DU145 cells or LNCaP cells.
Unpublished data by our lab have shown that miR-488* is expressed at
significantly low levels in androgen dependent cell line (LNCaP). However, no
signal for miR-488* was detected from androgen independent cell line DU145.
These results indicate that the miRNA processing machinery is functional to
some degree in LNCaP cells but not in DU145. Thus results from the proposed
experiment ( see above) with the total cellular extract from LNCaP or DU145
cell lines, could give us some insight whether what is observed from mature miR488* expression profiles is due to the inactivation of the miRNA processing
machinery in DU145 cells or is just simply due to the CG substitution.

These

experiments may provide an opportunity to identify RNA binding proteins unique
to miR-488* stem loop processing.
4.2 Identifying miR-488* precursor promoter:

Hsa-miR-488* is encoded in intron 5 of Astrotactin 1(ASTN1). Intron 5 is a
relatively large intron (4.9 kb) gene (Figure 24).

Figure 24: Schematic presentation of the genomic location of miR-488*: MiR-488* is hosted
by intron 5 of ASTN 1 gene and preceded by Exon 5, Intron 4 and Exon 4.

Intronic microRNAs studies suggested that microRNAs that reside in
introns, share the same promoters and regulatory elements of their host gene
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(Sikand et al., 2009).
Nevertheless,
miRNA

other

genes

believed

to

are
be

transcribed from their
own
Figure 25: mini gene construct to check for independent
promoter activity of miR-488*: including what we think to harbor
coding sequence for promoter of miR-488* in ASTN 1 gene. The
mini gene construct (Exon 4, intron 4, exon 5 and a segment of
intron 5 preceding precursor sequence of miR-488*) is to be
cloned into pGL4.20 promoterless luciferase plasmid.

promoters.

primary
have

Few

transcripts
been

identified

entirely
(Lagos-

Quintana et al., 2001; Bartel D P., 2001). Thus to truly understand whether miR488* has its own promoter or shares the same promoter of its host gene, we
could clone the mini gene system harboring Exon4, intron 4, Exon 5 and the
segment of intron 5 up to the start of the precursor sequence of miR-488* in the
promoterless pGL 4.20 luciferase vector plasmid (Figure 25). Consequently, after
transfection of the resulted plasmid into one of the cell lines which previously has
shown some levels of endogenous mature miR-488* profiles, we could assay
for luciferase activity. The detection of a luciferase activity could mean that the
mini gene system is harboring a promoter region. Then, we could identify that
specific promoter sequence together along any transcription factors docking sites
nearby.
The promoter sequence, if present, could be identified through truncation
process of the promoter region. Transcription factor’s docking sites, also if
present, could be first identified by prediction software’s followed by experimental
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validation. Thus these transcription factors and promoter sequence could be
used in future experiments for better understanding of the processing of miR488* in different cell lines as well as aiming in future for drug therapy in prostate
cancer by controlling the expression of miR-488*.
4.3 Library of miR-488* Target site:

The role of hsa-miR-488* in biological processes is not fully understood.
TARGETSCAN bioinformatic program has predicted many target sites for miR488* in the human genome. Some of these targets are encoded in genes
involved in Alternative splicing (LILRA2 gene). Some are involved in mRNA
splicing regulation spliceosome-associated protein (KIAA 1429 gene). Other play
a role in tumor suppression (ARMCX2 gene), and other may play a regulatory
role in RNA editing (ADARB2 gene) (Figure 26). These results implicate further

Figure 26: Examples of miR-488* targets sites in 3’UTR of their perspective genes:
Base pair interaction between miR-488* and target sites were predicted by TARGETSCAN
microRNA target prediction program and validated through RNAhybrid Algorithm.

58

importance of miR-488* in regulating biological processes. One of the future aims
is to build a genome wide library of miR-488* target sites in 3’UTR that allows us
to further study the implication of miR-488*.
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4.4 Conclusion:

A number of studies have provided insight into molecular mechanisms that
contribute to the onset and progression of prostate cancer. Androgens play an
important role in the development, regulation, and maintenance of the male
phenotype as well as the reproductive physiology and have been implicated in
the development and progression of prostate cancer. Androgens are required
mitogens for the survival and proliferation of prostate cells and most prostate
cancers are treated by complete blockade of androgen. AR is heterogeneously
expressed in primary tumors, and throughout the progression of hormonesensitive and hormone-refractory prostate cancers. AR is a prominent target for
the treatment of non-organ confined prostate cancer by hormonal blockade
therapy that uses anti-androgens to competitively inhibit the binding of androgen
to the ligand binding domain of the receptor. In prostate carcinogenesis, changes
in AR signaling pathways activate the growth of malignant cells. The hormonerefractory stage of the disease is commonly associated with the constitutive
activation of AR expression by unknown mechanisms.
Noncoding RNAs play diverse functions including structural, enzymatic
and regulatory in metazoan gene expression. Genes that are potentially targeted
by these miRNAs include cell growth and maintenance, signal transduction, cell
proliferation, phosphorylation, cell cycle, transcription factors, cell organization
and biogenesis etc. MiRNA mediates gene expression through translational
repression of its target by binding at the 3’ untranslated region. In this work, our
computational analysis has identified a target site of Hsa-miR-488* in the
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androgen receptor 3’ untranslated region.

The chimeric AR3’UTR luciferase

plasmid sensor experiment suggested that the predicted target site is an
authentic target site. Seed region within target is essential for the binding with
miR-488*. Four base pairs mutations to the seed region is enough to disrupt the
base paring interaction between that target site and the miR-488*. Furthermore,
western blot data shows repression in the expression of endogenous Human
androgen receptor in LNCaP cells by miR-488* mimic. Ectopically expressed
mature miR-488* has a dose dependent repression of Firefly luciferase reporter
plasmid. Stably expressed miR-488* in androgen dependent prostate cancer cell
line (LNCaP) showed slower growth comparing to the miR-488* stably
transfected androgen independent cell line (C4-2B).
In conclusion, miR-488* is down regulated in numerous prostate cancer
cell lines, suggesting a tumor-inhibitory function of Hsa-miR-488*. That being
said, further investigations are required to fully understand the molecular
mechanisms underlying the regulation of AR expression by miR-488*. Thus
further knowledge of the functions and the mechanisms of miR-488* expression
could significantly improve our understanding regarding the use of microRNAs as
a therapeutic interventions of prostate cancer.
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Appendices

Table 1: Host genes, chromosomes and miRNA distribution: The table illustrates
examples of conserved miRNAs with their host genes and gene IDs.

Hsa-mir-483
Mmu-mir-483
Rno-mir-483
Consensus

10
20
30
40
50
60
76
(1) 1
(1) GAGGGGGAAGACGGGAGGAAAGAAGGGAGUGGUUCCAUCACGCCUCCUCACUCCUCUCCUCCCGUCUUCUCCUCUC
(1) GAGGGGGAAGACGGGAGAAGAGAAGGGAGUGGUU---UUUGGGUGCCUCACUCCUCCCCUCCCGUCUUGUUCUCUC
(1) GAGGGGGAAGACGGGAGAAGAGAAGGGAGUGGUU---UUUGGGUGCCUCACUCCUCCCCUCCCGUCUUGUUCUCUC
(1) GAGGGGGAAGACGGGAGAAGAGAAGGGAGUGGUU
UUUGGGUGCCUCACUCCUCCCCUCCCGUCUUGUUCUCUC

Figure 1: Alignments of the stem loop of miRNAs 483 of human, mouse and rat :
The figure illustrates a representative dataset showing conserved sequence elements
found in stem loop sequences of the miRNA of human, mouse and rat. An 81.5% of
total conservation is observed.
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1

CCTCCTTGTC AACCCTGTTT TTCTCCCTCT TATTGTTCCC TACAGATTGC GAGAGAGCTG

61

CATCAGTTCA CTTTTGACCT GCTAATCAAG TCACACATGG TGAGCGTGGA CTTTCCGGAA

121

ATGATGGCAG AGATCATCTC TGTGCAAGTG CCCAAGATCC TTTCTGGGAA AGTCAAGCCC

181

ATCTATTTCC ACACCCAGTG AAGCATTGGA AACCCTATTT CCCCACCCCA GCTCATGCCC

241

CCTTTCAGAT GTCTTCTGCC TGTTATAACT CTGCACTACT CCTCTGCAGT GCCTTGGGGA

301

ATTTCCTCTA TTGATGTACA GTCTGTCATG AACATGTTCC TGAATTCTAT TTGCTGGGCT

361

TTTTTTTTCT CTTTCTCTCC TTTCTTTTTC TTCTTCCCTC CCTATCTAAC CCTCCCATGG

421

CACCTTCAGA CTTTGCTTCC CATTGTGGCT CCTATCTGTG TTTTGAATGG TGTTGTATGC

481

CTTTAAATCT GTGATGATCC TCATATGGCC CAGTGTCAAG TTGTGCTTGT TTACAGCACT

541

ACTCTGTGCC AGCCACACAA ACGTTTACTT ATCTTATGCC ACGGGAAGTT TAGAGAGCTA

601

AGTAATAGAC CCGAAATCAA AACAAAAACA AGCAAAC

Figure2: Androgen Receptor 3’ untranslated region. The figure illustrates the AR
3’UTR sequence (637 bases) with the predicted target site of miR-488* underlined and
highlighted in red color. Target site consists of 24 nucleotides between base 589 and
base 612.
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Figure 3: pMIR-Report and an assay for mRNA specific miR function. The figure
represents pMIR-Report Luciferase vector with the tow restriction sites (SpeI and HindII)
at the far ends of the MCS. Figure 3A and 3B are an illustration of the assay for AR
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3’UTR specific microRNA function. Figure 3A is a representation of luciferase gene
cloned downstream of CMV promoter. Figure 3B is the chimeric luciferase sensor
plasmid with AR3’UTR downstream of the luciferase gene.

A

Figure 4A: AR 3’ UTR with three substitution binding sites for miR-488*. miR-488*
substitution sites are indicated as site 1, site 2 and site 3. Bases are highlighted in red.
These three sites might serve as substitution targets for miR-488*.

B

Figure 4B: Schematic representation of segments of AR3’UTR cloned in pMIR
report vector. Full length AR3’UTR (637 bases) with the miR-488* predicted site is
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shown in green box. Site 1 (nucleotides 158-168 from 5’ end of AR 3’UTR) consists of
10 nucleotides with 7 perfect matches to the seed region. Site 2 (nucleotides 293-299
from 5’ end of AR 3’UTR) has 6 nucleotides with 4 perfect matches to the seed region
and Site 3 (nucleotides 348-358 from 5’ end of AR 3’UTR) is composed of 10
nucleotides with 8 perfect matches to the seed region. Short AR 3’UTR (77 bases)
spanning between nucleotide 561 and nucleotide 637.

Figure 5: Quantitative analysis of the repression of Luciferase sensor harboring
individual mutations to site 1 , site 2 and site 3 by miR-488* mimic. Repression
levels of firefly luciferase ( 54%, 53% and 52% ) for mutated site 1, mutated site 2 and
mutated site 3 respectively as compared to seed MUT AR 3’UTR with 51% firefly
luciferase repression.
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Figure 6: Pre-miR-488* expression vector. The 383bp segment of intron five of
ASTN1 containing precursor sequence for miR 488* and flanking region was PCR
amplified and cloned downstream of CMV promoter into the MCS of pcDNA 3.1 (-)
vector.
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Figure 7: TaqMan MicroRNA Assay. The step one shows the extraction of total RNA.
Step 2 illustrates the Reverse Transcription of RNA. The step 3 demonstrates the set up
of Singleplex taqMan microRNA Assay reaction. Finally, the step 4 shows the Real-time
PCR amplification followed by analysis of the data in step 5.
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